Impact of relative dose intensity on pathologic complete response in human epidermal growth factor receptor 2 positive breast cancer patients receiving neoadjuvant TCHP.

Kaylyn ColletteCassandra L PerkeyVal AdamsBrent J SheltonLauren S CorumAllison R Butts

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Patients who received ≥ 85% RDI had increased pCR rates compared to patients receiving <85% RDI. A larger patient population is needed to formulate definitive conclusions on the impact of RDI and pCR rates.

Keyphrases

epidermal growth factor receptor
positive breast cancer
locally advanced
tyrosine kinase
advanced non small cell lung cancer
rectal cancer
endothelial cells
neoadjuvant chemotherapy
squamous cell carcinoma
lymph node
case report
induced pluripotent stem cells
radiation therapy
real time pcr
high intensity